Cell-therapy due diligence for patients in the United States
A country-specific starting point for checking product authorisation, trial oversight and cross-border follow-up. This page does not rank providers or recommend medical travel.
What the regulator can confirm
In the United States, the FDA warns that many products marketed as regenerative medicine are unapproved. The agency also states that registration of a company or listing of a study on ClinicalTrials.gov does not by itself mean that a product may be marketed lawfully. Check the exact product and indication in the FDA's current cellular and gene therapy records rather than relying on the general term stem cells.
For treatment outside the United States, FDA status does not transfer automatically to another jurisdiction. Ask for the foreign regulator, legal route, product name, manufacturer and trial or authorisation number in writing. An independent clinician should review the evidence and the plan for complications and follow-up after you return home.
Evidence to request before treatment
| Question | Document or identifier | Why it matters |
|---|---|---|
| What exactly is administered? | Product name, cell source, processing, dose and route | Evidence and legal status are product- and indication-specific. |
| What is the legal route? | Marketing authorisation, authorised trial number, or named exemption and authority | A clinic licence or registry listing does not by itself authorise a product. |
| Who manufactures it? | Legal manufacturer, site and authorisation scope | General references to GMP are not a substitute for a current, applicable record. |
| How are harms managed? | Consent form, adverse-event plan, insurance and emergency contact | Experimental status does not remove the duty to disclose and manage risk. |
| What happens after travel? | Written follow-up plan and named clinician | Cross-border care can complicate continuity and reporting. |
Conditions compared
Educational regulatory orientation, reviewed in 2026. Verify current records directly with the authority and seek independent medical advice.